Accentia Biopharmaceuticals Receives Extension Of Exclusive Option To License All Antifungals For Chronic Sinusitis

TAMPA, Fla.--(BUSINESS WIRE)--July 24, 2006--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI - News) has signed an amendment to its exclusive option agreement with the Mayo Foundation for Medical Research and Education (Mayo Clinic) to license any and all intranasal antifungals for chronic sinusitis. The amendment extends the exclusive option agreement an additional year and will expire December 6, 2007 beyond the anticipated date of an NDA filing for SinuNase(TM). Accentia is developing SinuNase under an exclusive worldwide license with the Mayo Clinic for the use of intranasal amphotericin B for refractory chronic sinusitis.

Back to news